Alpha-proteinase inhibitor ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastrointestinal disease | 1 |
98. Eosinophilic gastrointestinal disease
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05485155 (ClinicalTrials.gov) | April 2023 | 1/8/2022 | Zemaira Eosinophilic Esophagitis Pilot Study | An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Alpha-proteinase inhibitor | Children's Hospital Medical Center, Cincinnati | CSL Behring;National Institutes of Health (NIH) | Not yet recruiting | 18 Years | 70 Years | All | 15 | Phase 2 | NULL |